Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort

Inclusion Criteria: * Age \>18 * Undergoing unilateral retrograde ureteroscopy with ureteral stent placement Exclusion Criteria: * Significant ureteral trauma * Concomitant ESWL or other secondary surgical procedure than may impact patient comfort * Subject with know hypersensitivity to alfuzosin hydrochloride or any component of alfuzosin hydrochloride tablets. * Pregnancy, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study * Undergoing bilateral ureteral stenting * Undergoing antegrade ureteral stenting * Undergoing simultaneous extracorporeal shockwave lithotripsy * Urinary infection (fever \>101, positive urine culture, many bacteria on urinalysis) * Primary bladder dysfunction that would impact ability to void without a catheter * Neurologic dysfunction that would impair pain sensation * History of chronic pain or substance abuse * Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased * Other alpha-blockers * Phosphodiesterase type 5 inhibitors for erectile function Any subject for whom the principal investigator feels it would not be in his or her best interest to participate in the study.